title: Recent advances in the management of Hodgkin lymphoma.
abstract: Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.
authors.affiliation: Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Jose C
authors.initials: JC
authors.lastname: Villasboas
authors.affiliation: Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
keywords: Hodgkin lymphoma; b lymphocytes; cancer; lymph nodes